Correction (DOI:10.1016/j.jcin.2009.10.001);Safety and Effectiveness of the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice. 12-Month Data From the E-Five Registry

JACC: Cardiovascular Interventions

Volumn 2, Issue 12, 2009, Pages 1227-1235

  Lotan, Chaim ^a   Meredith, Ian T ^b   Mauri, Laura ^c   Liu, Minglei ^d   Rothman, Martin T ^e  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b MonashHEART   (Australia)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MEDTRONIC INC   (United States)

^e LONDON CHEST HOSPITAL   (United Kingdom)

Author keywords

coronary artery lesion; drug eluting stent; multicenter registry; restenosis; stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ZOTAROLIMUS;

ADULT; ARTICLE; BARE METAL STENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STENT THROMBOSIS; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 72149103553     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2010.01.009     Document Type: Erratum

References (24)

1. Melikian N., and Wijns W. Drug-eluting stents: a critique. Heart 94 (2008) 145-152
2. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
3. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
4. Fajadet J., Wijns W., Laarman G.J., et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 114 (2006) 798-806
5. Jeremias A., and Kirtane A. Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention. Ann Intern Med 148 (2008) 234-238
6. Jain A.K., Meredith I.T., Lotan C., et al. Real-world safety and efficacy of the Endeavor zotarolimus-eluting stent: early data from the E-Five registry. Am J Cardiol 100 Suppl (2007) 77M-83M
7. Kandzari D.E., and Leon M.B. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. J Interv Cardiol 19 (2006) 405-413
8. Meredith I.T., Ormiston J., Whitbourn R., et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary lesions: Endeavor I trial. EuroIntervention 1 (2005) 157-164
9. Schultheiss H.P., Grube E., Kuck K.H., et al. Safety of direct stenting with the Endeavor stent: results of the Endeavor II continued access registry. EuroIntervention 3 (2007) 76-81
10. Kandzari D.E., Leon M.B., Popma J.J., et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 48 (2006) 2440-2447
11. Gershlick A., Kandzari D.E., Leon M.B., et al., ENDEAVOR Investigators. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. Am J Cardiol 100 Suppl (2007) 45M-55M
12. Lee C.H., Low A.F., Hong E.C., et al. Long-term safety and efficacy are observed after implantation of zotarolimus-eluting stent in real-world clinical practice. EuroIntervention 4 (2008) 338-344
13. Cutlip D.E., Windecker S., Mehran R., et al., Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
14. Urban P., Gershlick A.H., Guagliumi G., et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: 1-year follow-up of the e-Cypher registry. Circulation 113 (2006) 1434-1441
15. Simonton C.A., Brodie B., Cheek B., et al. Comparative clinical outcomes of paclitaxel and sirolimus-eluting stents: results from a large prospective multicenter registry-STENT group. J Am Coll Cardiol 50 (2007) 1214-1222
16. Waksman R., Buch A.N., Torguson R., et al. Long-term clinical outcomes and thrombosis rates of sirolimus-eluting versus paclitaxel-eluting stents in an unselected population with coronary artery disease (REWARDS registry). Am J Cardiol 100 (2007) 45-51
17. Lasala J.M., Cox D.A., Dobies D., et al. Usage patterns and 2-year outcomes with the TAXUS express stent: results of the ARRIVE 1 registry. Catheter Cardiovasc Interv 72 (2008) 433-445
18. Mauri L., Cutlip D.E., Leon M.B., et al. Long term safety results from the Endeavor clinical program: four-year follow-up. (abstr). Am J Cardiol 102 Suppl 1 (2008) 124i
19. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
20. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
21. Jeremias A., Sylvia B., Bridges J., et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 109 (2004) 1930-1932
22. Grines C.L., Bonow R.O., Casey Jr. D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 49 (2007) 734-739
23. Applegate R.J., Sacrinty M.T., Kutcher M.A., et al. "Off-label" stent thrombosis: 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol 51 (2008) 607-614
24. Roy P., Bonello L., de Labriolle A., et al. Two-year outcomes of patients treated with sirolimus- versus paclitaxel-eluting stents in an unselected population with coronary artery disease (from the REWARDS registry). Am J Cardiol 102 (2008) 292-297